$695 | Single User
$1395 | Global License

Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 13 Jul 2014 | 137 | In Stock
Related Topics: Lilly , Roche

Introduction

Scope



Two recent developments appear poised to shift the typical US-based treatment regimen for first-line metastatic colorectal cancer in patients with wild-type KRAS gene mutations: approval of Amgen's Vectibix in this setting and study data presented at the ASCO annual meeting from the CALGB80405 study comparing Bristol-Myers Squibb and Eli Lilly's Erbitux with Roche's Avastin in this indication.


Data from CALGB80405 suggest that Erbitux and Avastin – when used in combination with chemotherapy – yield comparable results for the treatment of metastatic colorectal cancer.


These recent developments will arguably have an adverse impact on sales of Avastin, which generates estimated annual global revenue (according to analysts at Credit Suisse) of .1 billion in colorectal cancer, of which around a third is thought to be generated in KRAS wild-type patients.


Of the estimated billion global market for metastatic colorectal cancer, the KRAS wild-type population accounts for around 60 percent of all cases. While Avastin – in combination with FOLFOX chemotherapy – dominates the 40 percent share of the market accounted for by patients with KRAS mutations, the wild-type segment is more competitive; Credit Suisse estimates that Avastin and Erbitux each account for around 40 percent of usage, with Vectibix accounting for the remaining 20 percent.


Puchase Reasons


To ascertain how these recent developments will impact the treatment paradigm for metastatic colorectal cancer, FirstWord is polling US-based oncologists. Specifically we are asking them...


  • What percentage of metastatic colorectal cancer KRAS wild-type patients are currently treated in the first-line setting with an EGFR inhibitor?

  • What percentage of first-line patients are treated with Erbitux?

  • To what percentage of first-line patients they expect to prescribe Vectibix to in 12 months time?

  • To what percentage of first-line patients they expect to prescribe Vectibix or Erbitux to in 12 months time?

  • Whether they are located in the cetuximab belt – an area of the US where patients treated with Erbitux are known to have a higher chance of suffering from infusion reactions?
  • Table of Contents
    for Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    137 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Bizwit Research and Consulting
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)
    • VPA Research